论文部分内容阅读
目的用含乌司他丁造影剂显影胰管,以观察ERCP术后胰腺炎的发生率和预防的临床对照研究。方法将2008年1月至2009年7月上海交通大学医学院附属仁济医院嘉定分院178例患者随机分成对照组85例、实验组93例,实验组用含乌司他丁造影剂显影胰管、而对照组用常规造影剂,操作要求用缓力推注造影剂且仅显示主胰管。结果178例发生ERCP术后胰腺炎共15例,发生率为8.9%,其中对照组11例、占12.9%(11/85),实验组4例、占4.3%(4/93),两组发生率比较差异有统计学意义P<0.05,诊断性ERCP术后胰腺炎发生率,对照组和实验组分别为44.4%(4/9)和14.3%(1/7),统计分析差异无统计学意义P>0.05。全部患者为轻型胰腺炎,经保守治疗痊愈。结论在ERCP术操作中使用含乌司他丁造影剂显影胰管,能降低ERCP术后胰腺炎的发生率,但不能完全避免术后胰腺炎的发生。
Objective To develop pancreatic duct with ulinastatin contrast agent to observe the incidence and prevention of pancreatitis after ERCP clinical control study. Methods From January 2008 to July 2009, 178 patients from Jiading Branch of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine were randomly divided into control group (n = 85) and experimental group (n = 93). Experimental group included ulinastatin contrast medium , While the control group with conventional contrast media, the operation requires bolus bolus contrast agent and only shows the main pancreatic duct. Results A total of 15 cases of pancreatitis occurred in 178 cases (8.9%), of which 11 cases (11/85) were in the control group and 4 cases (4.3%) in the experimental group (4/93) (P <0.05). The incidence of pancreatitis after diagnostic ERCP was 44.4% (4/9) and 14.3% (1/7) respectively in the control group and experimental group, with no statistic difference Significance of learning P> 0.05. All patients with mild pancreatitis, conservative treatment cured. Conclusions The use of ulinastatin contrast medium to develop pancreatic duct during ERCP operation can reduce the incidence of pancreatitis after ERCP, but can not completely avoid the occurrence of postoperative pancreatitis.